A panel NGS analysis involving 8085 Chinese breast cancer patients revealed only 18 (0.3%) carriers of pathogenic CHEK2 mutations [141]; eight of them carried the novel founder nonsense mutation c.C417A (p.Y139*) [142]. This evidence concerns the gene CHEK2 and breast cancer.